Summary

Despite the advent of dual antiplatelet therapy with aspirin and clopidogrel, rates of in-hospital and 1-year mortality and reinfarction after acute coronary syndrome (ACS) are approximately 10%. The results of the ATLAS ACS-TIMI 46 [NCT00402597] trial represent an important step toward meeting a need for more effective antithrombotic therapy after ACS.